Rachel Liang, M.S., PMP, is the Senior Director and Head of PMO at Arialys Therapeutics, where she founded the company’s Project Management Office and established the infrastructure supporting portfolio governance, strategic planning, and cross-functional program execution. Rachel brings more than 20 years of leadership experience across biotechnology, gene and cell therapy, molecular diagnostics, and in vitro diagnostics, with deep expertise in building PMOs, leading global cross-functional teams, and advancing programs from early research through regulatory submissions and commercialization. She has successfully led cross-functional development teams from early-stage development through commercialization, including pre-IND, IND, BLA, 510(k), CE-IVDR, and NMPA filings across rare disease, oncology, infectious disease, and reproductive health programs. Prior to Arialys, Rachel held leadership roles at Bionano, Fate Therapeutics, and Novartis Gene Therapies (formerly Avexis), where she built PMO functions, directed portfolio strategy, and led development initiatives across AAV gene therapy, CAR-T, CAR-NK, iPSC cell therapy, and rare disease diagnostic platforms. Earlier in her career, she contributed to the successful launch of more than 12 multiplex assays across 10 instrument platforms at companies including Illumina, Agena Bioscience, GenMark, and Quidel. Rachel holds an M.S. in Molecular Biology from New Mexico Tech and is a certified Project Management Professional (PMP).